Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Legend: a: Forteo, b: CinnoPar, P1NP: Procollagen Type 1 N-Terminal Propeptide, BSAP: Bone-Specific Alkaline Phosphatase, CTX: C-terminal cross-linking telopeptide, OC: Osteocalcin, NTX: N-terminal telopeptide of type 1 collagen, C1CP: C-Propeptide of Type 1 Procollagen, Ca: Calcium, 25-OHD: 25 hydroxyvitamin D, NS: non-significant
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Double-blind reported · Human research reported
Reported blinded roles: patients.
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial
Source: Article title.
Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial
Source: Article title.
Overall, 104 osteoporotic postmenopausal women aged 45 to 75 yr were randomized to receive 20 μg daily subcutaneous injections of either Forteo® or CinnoPar® for 6-months from 2011 to 2012.
Source: Abstract.
All the participants in this study, including patients, physicians, and nurses were blinded to the treatment allocation.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial
Randomised controlled trial · Iranian Journal of Public Health · 2018
Original publication title
Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial
Copyright© Iranian Public Health Association & Tehran University of Medical Sciences
Original publication · CC BY 3.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Due to high cost and burden of osteoporosis, it is reasonable to focus on the reduction of fractures as the main goal of treatment. We compared the efficacy and safety of a new biosimilar recombinant human parathyroid hormone (CinnoPar®, CinnaGen, Iran) to the reference product (Forteo®, Eli Lilly, USA) in a randomized double-blind clinical trial (RCT).
Source: Background:Abstract: What methods does the paper describe?
Overall, 104 osteoporotic postmenopausal women aged 45 to 75 yr were randomized to receive 20 μg daily subcutaneous injections of either Forteo® or CinnoPar® for 6-months from 2011 to 2012. Bone biomarkers were measured at baseline, and during first, third, and sixth month’s follow-up along with lumbar spine, total hip, and femoral neck bone mineral density (BMD) assessment at the baseline and six months after that. The study was registered in Iranian registry of clinical trials under the registration number of IRCT138810121414N5. The endpoints were to compare bone biomarkers, BMD and drug safety between groups.
Data analysis was performed using SPSS 11.
Source: Methods:Abstract: Results
Age range of ninety-four patients who completed the study was 42 to 81 yr. Participants were divided into Forteo (45 subjects) and CinnoPar (49 subjects) groups. No significant difference in terms of bone biomarkers or BMD scores was shown between groups (P≥0.05). The most prevalent side effects were hypercalcemia and hypercalciuria without any significant statistical differences between groups.
Source: Results:Abstract: Conclusion
CinnoPar® can be considered as a good alternative therapy for Forteo® in postmenopausal osteoporotic women due to its comparable efficacy and safety properties.
Source: Conclusion:Authors’ abstract
Background:
Due to high cost and burden of osteoporosis, it is reasonable to focus on the reduction of fractures as the main goal of treatment. We compared the efficacy and safety of a new biosimilar recombinant human parathyroid hormone (CinnoPar®, CinnaGen, Iran) to the reference product (Forteo®, Eli Lilly, USA) in a randomized double-blind clinical trial (RCT).
Methods:
Overall, 104 osteoporotic postmenopausal women aged 45 to 75 yr were randomized to receive 20 μg daily subcutaneous injections of either Forteo® or CinnoPar® for 6-months from 2011 to 2012. Bone biomarkers were measured at baseline, and during first, third, and sixth month’s follow-up along with lumbar spine, total hip, and femoral neck bone mineral density (BMD) assessment at the baseline and six months after that. The study was registered in Iranian registry of clinical trials under the registration number of IRCT138810121414N5. The endpoints were to compare bone biomarkers, BMD and drug safety between groups.
Data analysis was performed using SPSS 11.
Results:
Age range of ninety-four patients who completed the study was 42 to 81 yr. Participants were divided into Forteo (45 subjects) and CinnoPar (49 subjects) groups. No significant difference in terms of bone biomarkers or BMD scores was shown between groups (P≥0.05). The most prevalent side effects were hypercalcemia and hypercalciuria without any significant statistical differences between groups.
Conclusion:
CinnoPar® can be considered as a good alternative therapy for Forteo® in postmenopausal osteoporotic women due to its comparable efficacy and safety properties.
Publication and source details
Original title: Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial
Ozra TABATABAEI-MALAZY; Masumeh NORANI; Ramin HESHMAT; Mostafa QORBANI; Afsaneh VOSOOGH; Behnaz AFRASHTEH; Farzin KAHKESHAN; Arman AJAMI; Bagher LARIJANI
Iranian Journal of Public Health · 2018
* Corresponding Author: Email: emri@tums.ac.irCopyright© Iranian Public Health Association & Tehran University of Medical Sciences2018https://creativecommons.org/licenses/by/3.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T18:59:04.469893+00:00
DOI: · PMC6174042